ESGO 2020 Highlights

The efficacy and safety of treatment with niraparib was similar in older patients and in those aged 65 years. An individualized starting dose decreased the rate of thrombocytopenia adverse events in older patients. Read More ›

An on-demand online video panel discussion regarding the use of PARP inhibitors in patients with newly diagnosed advanced ovarian cancer resulted in a positive educational impact among oncologists and obstetrician-gynecologists. Read More ›

Population-based personalized ovarian cancer risk stratification is feasible and acceptable. Participants reported high satisfaction without a negative impact on psychological health or quality of life. Read More ›

The level of CA 19-9, expression of HE4, and the presence of massive ascites or positive lymph nodes are important prognostic factors for overall survival in patients with ovarian clear-cell carcinoma. Read More ›

In the MIRRORS study, researchers aim to determine the feasibility of a randomized controlled trial of robotic interval debulking surgery for patients with ovarian cancer. While robotic surgery is unlikely to be suitable for all cases of ovarian cancer, researchers hope that robotic surgery may provide improved quality of life and recovery in selected women. Read More ›